First molecules discovered using artificial intelligence head to development

IMAGE: The first drug-candidate compounds targeting age-related diseases discovered using AI are licensed for development. Jan.6, 2018, Baltimore, Maryland- Insilico Medicine, Inc. ("Insilico"), a Baltimore-based next-generation artificial intelligence (AI) company specializing in the application of deep learning for drug discovery, announces that Juvenescence.AI, its joint venture with Juvenescence Limited ("Juvenescence"), has licensed its first compound family for clinical development. This is one of five compound families that Juvenescence.AI is able to license each year under its license agreement with Insilico. "The selection of our first compound family is a landmark event for Juvenescence, and a broader comment on the potential of AI to transform the drug discovery and development industry" commented Jim Mellon, Chairman of Juvenescence. This deal is a result of a deep collaboration between the senior drug developers at Juvenescence and AI experts at Insilico and signifies a new era in drug discovery where highly sophisticated AI finds viable drug candidates.